Ads
related to: vascular dementia and alzheimer's combination drugs and medications approved
Search results
Results from the WOW.Com Content Network
Not only that, they had a 52 percent lower risk of vascular dementia, and a 39 percent lower risk of Alzheimer’s dementia. People who took SGLT-2 inhibitors for longer periods of time seemed to ...
The study authors wanted to understand more about how the combination and long-term use of cardiovascular medications affected dementia risk in a more generalized population.
Heart problems can increase dementia risk, but a new study suggests that heparin, a common anticoagulant administered via injection, may help delay Alzheimer’s onset.
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
Memantine/donepezil, sold under the brand name Namzaric among others, is a fixed dose combination medication used for the treatment of dementia of the Alzheimer's type. [1] It contains memantine, as the hydrochloride, a NMDA receptor antagonist; and donepezil as the hydrochloride, an acetylcholinesterase inhibitor. [1] It is taken by mouth. [1]
Donepezil has been tested in other cognitive disorders, including Lewy body dementia, [33] and vascular dementia, [34] but it is not currently approved for these indications. Donepezil has also been found to improve sleep apnea in people with Alzheimer's. [35] It also improves gait in people with mild Alzheimer's. [36]
When the scientists looked at dementia subtypes, they found that SGLT-2 inhibitors were linked to 52% lower risk of vascular dementia, and 39% lower risk of Alzheimer’s disease.
Vascular dementia is the second-most-common form of dementia after Alzheimer's disease in older adults. [4] The prevalence of the illness is 1.5% in Western countries and approximately 2.2% in Japan. It accounts for 50% of all dementias in Japan, 20% to 40% in Europe and 15% in Latin America. 25% of people with stroke develop new-onset dementia ...
Ads
related to: vascular dementia and alzheimer's combination drugs and medications approved